Department of Pathology and Laboratory Medicine, Temple University Hospital, Temple University, Philadelphia, PA, United States of America.
American Red Cross, Temple University, Philadelphia, PA, United States of America.
Blood Transfus. 2018 May;16(3):293-301. doi: 10.2450/2017.0274-16. Epub 2017 Apr 5.
RhD variants have altered D epitopes and/or decreased antigen copies per red cell. Individuals carrying these variants may test antigen negative, weakly positive, or positive by serology, and may or may not be at risk of alloimmunisation after exposure. There have been recommendations to perform RHD genotyping of patients, pregnant women and females of childbearing potential with serological weak D phenotype, to guide prophylactic use of Rh immune globulin (RhIG), and better conserve D-negative blood products. The purpose of this study was to evaluate the performance of a set of empirical criteria to identify such patients.
A two-method strategy of gel testing (GT) and tube testing (TT) was used for Rh typing of patients with no historical blood type in the present institution. A monoclonal-polyclonal blend anti-D was used for Rh typing by TT at immediate spin. Three empirical criteria were used to identify candidates for genotyping: C1: discrepancy between the two test methods and a GT reaction strength >2+ stronger than TT; C2: weak serological reaction, defined as reaction strength ≤2+ regardless of testing method if both GT and TT were performed or reaction strength ≤2+ if only GT was performed, or reaction strength ≤1+ if only TT was performed; C3: presence of anti-D in D-positive patients with no history of RhIG use in the preceding 3 months and in whom alloanti-D is suspected.
Overall, 50 patients, ranging from newly born to 93 years old, were identified. Genomic testing confirmed D variants in 49/50 cases with a positive predictive value of 98%.
This two-method strategy is a powerful screening tool for identifying candidates for RHD genotyping. This strategy meets the current requirements of two blood type determinations/two specimens in pre-transfusion testing while simultaneously identifying candidates for RHD genotyping with a minimal increase in work load and cost.
RhD 变异体改变了 D 表位和/或每个红细胞的抗原拷贝数减少。携带这些变异体的个体可能通过血清学检测呈抗原阴性、弱阳性或阳性,并且在接触后可能有或可能没有发生同种免疫的风险。已经有建议对血清学弱 D 表型的患者、孕妇和有生育能力的女性进行 RHD 基因分型,以指导 Rh 免疫球蛋白(RhIG)的预防性使用,并更好地保存 D 阴性血液制品。本研究的目的是评估一组经验标准来识别此类患者。
对本机构无既往血型史的患者采用凝胶试验(GT)和试管试验(TT)的双方法策略进行 Rh 定型。立即旋转时使用单克隆-多克隆混合抗-D 进行 TT 型 Rh 定型。使用三种经验标准来识别基因分型的候选者:C1:两种测试方法之间的差异以及 GT 反应强度比 TT 强>2+;C2:弱血清学反应,定义为无论 GT 和 TT 是否均进行,如果 GT 反应强度≤2+,或者仅 GT 进行时反应强度≤2+,或者仅 TT 进行时反应强度≤1+;C3:在没有 RhIG 使用史的 3 个月内且怀疑存在同种异体抗-D 的 D 阳性患者中存在抗-D。
总体而言,确定了 50 名患者,年龄从新生儿到 93 岁不等。基因组测试在 50 例中有 49 例证实存在 D 变异体,阳性预测值为 98%。
这种双方法策略是一种强大的筛选工具,可用于识别 RHD 基因分型的候选者。这种策略满足了当前输血前检测中两次血型测定/两个标本的要求,同时通过最小增加工作量和成本来识别 RHD 基因分型的候选者。